Physician profile
Michael H Mcghee
NPI 1750358552
$8,141.46
in general payments reported to CMS, 2019-2025
28 companies · $1,024 in 2025
The $1,024 reported for 2025 was more than what 81% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $663 · 2021: $988 · 2022: $662 · 2023: $3,932 · 2024: $546 · 2025: $1,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,465 · Food and Beverage: $2,037.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,465.00 |
| Food and Beverage | $2,037.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $4,089.18 | 2021-2024 | Austedo, Austedo Xr, Uzedy |
| Vanda Pharmaceuticals INC. | $704.37 | 2020-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $509.18 | 2020-2025 | Ingrezza |
| Lundbeck LLC | $497.29 | 2019-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $407.13 | 2019-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $280.98 | 2021-2024 | Trintellix |
| Jazz Pharmaceuticals INC. | $254.55 | 2019-2024 | |
| Abbvie INC. | $216.23 | 2021-2025 | |
| Noven Therapeutics, LLC | $190.72 | 2020-2025 | Xelstrym, Secuado |
| E.R. Squibb & Sons, L.L.C. | $144.77 | 2025 | Cobenfy |
| Alkermes, INC. | $133.97 | 2021-2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $133.75 | 2020-2022 | |
| Eisai INC. | $119.00 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $72.76 | 2021-2024 | Spravato |
| Avadel Cns Pharmaceuticals, LLC | $52.15 | 2023-2024 | Lumryz |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $39.33 | 2019 | |
| Almatica Pharma LLC | $37.52 | 2021 | |
| Allergan, INC. | $35.46 | 2019-2020 | |
| Axsome Therapeutics, INC. | $32.62 | 2022-2023 | Auvelity |
| Corium, LLC | $32.35 | 2023 | Azstarys |
| Idorsia Pharmaceuticals US INC | $31.10 | 2023 | Quviviq |
| Uswm, LLC | $28.83 | 2021 | |
| Acadia Pharmaceuticals INC | $21.22 | 2019 | |
| Bausch Health US, LLC | $18.21 | 2019 | |
| Neuronetics, INC. | $17.39 | 2021 | |
| Avanir Pharmaceuticals, INC. | $16.27 | 2019 | |
| Indivior INC. | $12.78 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $12.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mcghee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.